Recent Company News

• 09:41 PM ET Jul 13, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 08:16 PM ET Jul 29, 2025
  

  Alterity Therapeutics reports Q4 net cash from / (used in) operating activities (A$2.4M) - Appendix 4C (A$0.01, 0.00)

• 08:04 PM ET Jul 27, 2025
  

  Alterity Therapeutics reports positive topline data from open-label phase 2 clinical trial of ATH434 in multiple system atrophy (A$0.02, 0.00)

• 08:21 PM ET Jul 23, 2025
  

  Alterity Therapeutic's neuroimaging measure developed in bioMUSE Natural History Study featured in Annals of Clinical and Translational Neurology (A$0.01, 0.00)

• 09:41 PM ET Jul 10, 2025
  

  StreetAccount Summary - Australia unusual volume traders

• 07:25 PM ET Jul 13, 2025
  

  Alterity Therapeutics responds to ASX query; not aware of information that could explain recent trading in Company's securities (A$0.02, 0.00)